Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid

Completed · Phase 3

Conditions studied: Osteoporosis

In brief

The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.

Key facts

Study ID: NCT00097812
Run by: Novartis Pharmaceuticals
People needed: 220
Starts: 2004-05-01
Expected to finish: 2005-12-01
Last updated by the study team: 2012-04-27

Who can join

Age: 45 and older, up to 79. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Post-menopausal women between 45 and 79 years of age
Must be osteopenic/osteoporotic
Treatment with oral bisphosphonate for at least 1 year

You may not qualify if…

Any woman of child bearing potential
Treatment with other bone active agents
Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

The Permanente Medical Group — Santa Rosa, California, United States
Colorado Center for Bone Research — Lakewood, Colorado, United States
Florida Medical Research Institute — Gainsville, Florida, United States
Radiant Research — Stuart, Florida, United States
University of Kansas School of Medicine/ Division of Endocrinology — Kansas City, Kansas, United States
Clinical Pharmacology Study Group — Worcester, Massachusetts, United States
Arthritis Center of Nebraska — Lincoln, Nebraska, United States
Creighton University Osteoporosis Research Center — Omaha, Nebraska, United States
Oregon Osteoporosis Center — Portland, Oregon, United States
University of Pittsburgh — Pittsburgh, Pennsylvania, United States
Radiant Research — Wyomissing, Pennsylvania, United States
Puget Sound Osteoporosis Center — Seattle, Washington, United States
Novartis — Nuremberg, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.